News releases

December 12, 2016
-Plans to Initiate Single Pivotal, Open-Label, Single-Arm Phase 3 Clinical Trial in First Quarter of 2017- Ra'anana, Israel, New York, NY, December 12, 2016: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its Investigational New
February 8, 2016
Appoints Stuart Holden, M.D., to its Board of Directors and  Mark Schoenberg, M.D., as Medical Director New York, NY and Ra'anana, Israel, February 8, 2016: UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological